Clinical Trial

Study With Phage for CF Subjects With Pseudomonas Lung Infection

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-28; most recent amendment 2025-07-17.
Status change: Not Yet Recruiting → Recruiting 2025-07-16
Trial Details
NCT Number NCT06998043
Lead Sponsor BiomX Ltd
Conditions Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Enrollment 63 participants
Start Date 2025-07-02
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-07-22